Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
Citi Slashes Bitcoin Target to $82K

Citi Slashes Bitcoin Target to $82K

UTodayUToday2026/07/02 13:15
By:UToday

Wall Street giant Citi has revised its 12-month price targets for both Bitcoin (BTC) and Ethereum (ETH). 

The reversal has been attributed to pitiful exchange-traded fund (ETF) outflows and a stagnant legislative environment.

Citi has slashed its BTC forecast down to $82,000 and its ETH target to $2,200. 

They previously expected BTC to reach much higher targets due to the anticipation of much bigger institutional flows. 

The market's momentum has stalled mainly due to a lack of legislative progress ahead of the midterms. The bank's base-case scenario now assumes exactly zero new BTC ETF inflows over the next 12 months.

"The lack of legislative progress and negative sentiment in the sector has seen a reversal of flows YTD," the Citi report stated. "The average ETF holder is now underwater, and prices are below their pre-2024 US election levels." 

"De-basement fears" could theoretically drive renewed interest, but the hawkish macroeconomic conditions have reduced such risks. 

Just months ago, in December 2025, a joint report by various Citi analysts set a 12-month base-case target of $143,000 for Bitcoin.

The forecast was predicated on the expected passage of U.S. digital-asset legislation (specifically the Clarity Act). In that same December 2025 report, Citi outlined a bull case where BTC could reach $189,000 due to heightened end-investor demand.

Bitcoin's terrible year 

Earlier this year, Bitcoin peaked above the $96,000 level. After this, BTC suffered a huge price correction, eventually declining to roughly $60,000 by late February. 

The price was pushed back up to form a lower high near $80,000 by late May. After this, consecutive weeks of heavy sell-offs forced BTC back to the $59,000 range.

Will there be another bull run?

The short-term outlook appears to be exceptionally bleak, but CryptoQuant CEO Ki Young Ju recently noted that a macro breakout is still possible. It would require much bigger institutional allocations, according to the analyst. 

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

The "Outlier" Investment Art in the New Era of Berky

他山之石观投资2026/09/14 09:22
The "Outlier" Investment Art in the New Era of Berky

Chevron (CVX.US) explores alternative hedging for Middle East supply disruptions: targets Argentina and the Mediterranean to drive global LNG growth, seeks deal with India

Chevron is focusing on Argentina and the Mediterranean region, seeking global growth in liquefied natural gas, and plans to reach an agreement with India.

智通财经2026/09/14 09:12
Chevron (CVX.US) explores alternative hedging for Middle East supply disruptions: targets Argentina and the Mediterranean to drive global LNG growth, seeks deal with India

Energy and food price pressures intensify, potentially triggering an inflation rebound! The Bank of England may struggle to remain "calm" as market rate hike bets surge

The upward pressure on energy prices caused by the unresolved Middle East war is mounting. New risks are also approaching, which may keep inflation above the Bank of England’s 2% target for most of next year.

智通财经2026/09/14 08:57
Energy and food price pressures intensify, potentially triggering an inflation rebound! The Bank of England may struggle to remain "calm" as market rate hike bets surge

AstraZeneca (AZN.US) Breast Cancer Drug Etcamah Faces Setback in Phase III Clinical Trial, Potentially Impacting Billions in Sales

Bloomberg Intelligence analyst John Murphy stated that the setback in AstraZeneca's breast cancer drug trial could reduce sales in 2035 by $2.6 billion to $3.8 billion.

智通财经2026/09/14 08:41
AstraZeneca (AZN.US) Breast Cancer Drug Etcamah Faces Setback in Phase III Clinical Trial, Potentially Impacting Billions in Sales